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LETTERS TO THE EDITOR
Regarding “Anticoagulation with enoxaparin versus
intravenous unfractionated heparin in postoperative
vascular surgery patients”
In their recent article, Hingorani et al1 evaluated postoperative
anticoagulation therapy in patients after vascular surgery. They
compared therapeutic doses (1 mg/kg q12h) of enoxaparin, a low
molecular weight heparin (LMWH) with intravenous unfraction-
ated heparin and concluded that use of enoxaparin is safe and
effective. Likewise, we recently reported the results of a similar but
prospective study in patients undergoing lower extremity revascu-
larization.2
Although the purpose of neither study was to discuss the
indications for postoperative anticoagulation therapy, both enox-
aparin and unfractionated heparin were used as transitional therapy
to oral warfarin sodium. The rationale for their use is derived from
studies that show that unfractionated heparin and LMWH have
similar effects on suppression of neointimal hyperplasia in its early
stages of development.3 Because neointimal hyperplasia is a signif-
icant factor in postoperative progression of recurrent occlusive
disease, use of enoxaparin seems reasonable in patients in whom
postoperative anticoagulation therapy is necessary.
Enoxaparin is an interesting alternative to unfractionated hep-
arin because of its easy subcutaneous administration, better bio-
availability, lesser induction of thrombocytopenia, longer half-life,
and more predictable anticoagulant response.2,4,5 Cost analysis
favors enoxaparin because it does not require frequent monitoring
of prothrombin time, is easily administered subcutaneously and
therefore does not require intravenous continuous drip, and re-
duces overall postoperative length of stay on average by 2 to 2.5
days.1,2 The shorter hospital stay is because patients receiving
enoxaparin can be discharged and given outpatient therapy, even if
the international normalized ratio is not adequate with oral anti-
coagulation therapy alone.
One of the major concerns about postoperative anticoagula-
tion therapy is related to the possible increased incidence of com-
plications. Although Hingorani et al do not report which patients
were receiving enoxaparin and which ones were receiving unfrac-
tionated heparin, they report an 8% (6 of 77) rate of graft throm-
bosis in femoropopliteal bypass procedures and 11% (12 of 114)
rate for failing grafts in femorodistal bypass procedures. Their
overall graft thrombosis rate requiring return to surgery was statis-
tically significant (P  .02) in favor of the enoxaparin group. We
should emphasize that because enoxaparin or unfractionated hep-
arin was used as a bridge to oral anticoagulation therapy, the early
postoperative outcome (within the first 30 days) is what would
most likely be affected by any of such therapies. In our study, the
early graft thrombosis rate was 0% (0 of 35) for the enoxaparin
group. For the unfractionated heparin group the rate was 0% in
femoropopliteal bypass procedures and 4% (1 of 25) in femorodis-
tal bypass procedures.
Hingorani et al mention a higher incidence of wound hema-
toma when LMWH is started before 24 hours. This has not been
our experience. We started enoxaparin 6 hours postoperatively in
all patients and found a 6% (2 of 35) rate of bleeding complication,
which compares favorably with an 11% (4 of 35) rate for unfrac-
tionated heparin.
In conclusion, although more studies need to be done in
patients undergoing vascular surgery, enoxaparin may be consid-
ered a therapeutic alternative to unfractionated heparin. Enoxapa-
rin therapy will most likely replace unfractionated heparin therapy
in patients requiring postoperative therapeutic anticoagulation.
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